A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIb Clinical Trial Evaluating the Efficacy and Safety of Mecasin (KCHO-1) in Adults with Amyotrophic Lateral Sclerosis

Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive muscle weakness and paralysis, with respiratory failure being the leading cause of death. Mecasin (KCHO-1), a standardized botanical extract, has demonstrated neuroprotective and anti-neuroinflammatory effects in preclinical studies. A 12-week phase IIa trial suggested a potential benefit in slowing functional decline. This phase IIb trial evaluated the efficacy and safety of Mecasin over 24 weeks, including respiratory-related outcomes. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial, 50 patients were randomized to receive Mecasin (2.4 g/day) or placebo for 24 weeks, with both groups receiving riluzole (100 mg/day). Forty-three patients were included in the efficacy analysis. The primary endpoint was change in the Korean version of the ALS Functional Rating Scale-Revised (K-ALSFRS-R) total score. Respiratory-related assessments included orthopnea, FEV1/FVC, and end-tidal CO2, alongside safety evaluations. Results: At week 24, K-ALSFRS-R changes were −3.65 and −3.74 points in the Mecasin and placebo groups, respectively, with no significant between-group difference (estimated difference, 0.27; 90% CI, −1.80 to 2.33; p = 0.4146). Significant between-group differences were observed in FEV1/FVC (7.69 percentage points; p = 0.0036) and end-tidal CO2 (−3.92 mmHg; p = 0.0076). Linear mixed-effects models showed significant group-by-visit interactions for orthopnea (p = 0.0212) and FEV1/FVC (p = 0.0228). Adverse-event frequencies were comparable. Conclusions: Although Mecasin did not show a significant effect on the primary outcome (K-ALSFRS-R total score), the observed differences in respiratory-related outcomes provide a clinical rationale for further investigation in larger trials focusing on respiratory function.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-19
DOI
https://doi.org/10.3390/jcm15229076
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIb Clinical Trial Evaluating the Efficacy and Safety of Mecasin (KCHO-1) in Adults with Amyotrophic Lateral Sclerosis

Eunhye Cha, Hyung-Won Kang, Bong-Keun Song, Joonyoung Shin et al.
Journal of Clinical Medicine
Amyotrophic Lateral Sclerosis Research
article

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIb Clinical Trial Evaluating the Efficacy and Safety of Mecasin (KCHO-1) in Adults with Amyotrophic Lateral Sclerosis

Eunhye Cha, Hyung-Won Kang, Bong-Keun Song, Joonyoung Shin, Sungchul Kim, Boncho Uk Ku, Ilhong Son, Wookcheol Seo, Dongwoon Han, Taeseong Jeong, Dongwoung Kim, Hyorin Lee
article en

Abstract

Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive muscle weakness and paralysis, with respiratory failure being the leading cause of death. Mecasin (KCHO-1), a standardized botanical extract, has demonstrated neuroprotective and anti-neuroinflammatory effects in preclinical studies. A 12-week phase IIa trial suggested a potential benefit in slowing functional decline. This phase IIb trial evaluated the efficacy and safety of Mecasin over 24 weeks, including respiratory-related outcomes. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial, 50 patients were randomized to receive Mecasin (2.4 g/day) or placebo for 24 weeks, with both groups receiving riluzole (100 mg/day). Forty-three patients were included in the efficacy analysis. The primary endpoint was change in the Korean version of the ALS Functional Rating Scale-Revised (K-ALSFRS-R) total score. Respiratory-related assessments included orthopnea, FEV1/FVC, and end-tidal CO2, alongside safety evaluations. Results: At week 24, K-ALSFRS-R changes were −3.65 and −3.74 points in the Mecasin and placebo groups, respectively, with no significant between-group difference (estimated difference, 0.27; 90% CI, −1.80 to 2.33; p = 0.4146). Significant between-group differences were observed in FEV1/FVC (7.69 percentage points; p = 0.0036) and end-tidal CO2 (−3.92 mmHg; p = 0.0076). Linear mixed-effects models showed significant group-by-visit interactions for orthopnea (p = 0.0212) and FEV1/FVC (p = 0.0228). Adverse-event frequencies were comparable. Conclusions: Although Mecasin did not show a significant effect on the primary outcome (K-ALSFRS-R total score), the observed differences in respiratory-related outcomes provide a clinical rationale for further investigation in larger trials focusing on respiratory function.

Journal of Clinical MedicineVol. 15(22)
Kwangju Christian Hospital (KR), Korea Institute of Oriental Medicine (KR), Wonkwang University Sanbon Hospital (KR), Hanyang University (KR), Wonkwang University (KR), Gwangju University (KR)
Amyotrophic Lateral Sclerosis Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon